Matthias Essenpreis

Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

miacom diagnostics GmbH develops and distributes rapid molecular diagnostic tests for the identification of pathogens directly from patient material. Its products include hemoFISH Gram, hemoFISH Masterpanel, hemoFISH S.aureus and CNS Screen, respiFISH HAP Gram Panel, respiFISH HAP Masterpanel, FISH Probes, Combined hotplate and hybridization chamber, 8-channel pipette, and fluorescence microscopes. The company was founded by Ian Thrippleton and Walter Freiherr von Stein in 2009 and is headquartered in Düsseldorf, Germany.

Ventac Partners GMBH offers life sciences consultancy services. Its consulting services include due diligence, education and training, market analysis, product development and valuation. The company was founded by Mikael Oerum in 2002 and is headquartered in Munich, Germany.

Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation.

Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA.

GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.

IXRF Systems, Inc. designs and manufactures software and hardware for the micro-analysis and x-ray fluorescence industries. Its products include micro-XRF, mobile -XRF, vacuum devices, stages, upgrades, sdd detectors. The company was founded in 1993 and is headquartered in Austin, TX.

BroadOak Capital Partners LLC (BroadOak Capital Partners) is a private equity firm founded in 2006 by Bill Snider and Lars Hanan. The firm is headquartered in Maryland.

Biolog, Inc. enages in the manufacture of diagnostic substances. It offers microbial identification, phenotype microarrays for microbial and mammalian cells, mitochondria function assays, educational porta, microbiome, microbial community analysis, and microbial detection. The company was founded by Barry R. Bochner and Donald W. Barnby in 1984 and is headquartered in Hayward, CA.

Omniome, Inc. provides biotechnical research services. The firm's biosensors can be adopted for mobile diagnostics and health monitoring applications. The company was founded by Kandaswamy Vijayan in 2013 and is headquartered in San Diego, CA.

Optofluidics, Inc. operates as a scientific instrumentation company. It commercializes proprietary nano-technological devices to perform particle analysis and nano-manipulation applications for the life science and materials industries. The firm?s products include Hexpoint, NT Surface and Nano Tweezer. The company was founded by Bernardo Cordovez, Robert Hart and David Erickson in 2010 and is headquartered in Philadelphia, PA.

Part of Microsoft Corp., Anyware Fast is a company that develops 3-D and 2-D computer applications. The company is based in San Jose, CA. The company was founded by Robert H. Wicke. Anyware Fast was acquired by Dimension X on September 25, 1996.

Elastrin Therapeutics, Inc. is a biotech company based in Simpsonville, SC. Elastrin Therapeutics is developing novel therapies to reverse cardiovascular disease using a proprietary platform that targets and restores degraded elastin by removing harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. The company's treatment, a nanoparticle that specifically targets elastin, is able to reverse calcification in the arteries and other tissues, providing a solution to heart disease, stroke, high blood pressure, COPD, and aneurysm. The company was founded by Mirko Stange, Douglas Mulhall, Naren Vyavahare, Charles D. Rice, Valentin Busch, and Markus Zils. The CEO is Matthias Breugelmans.